WCLC 2025 - Posters & ePosters-EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC

EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC

Back to course

Pdf Summary

This real-world study, named Brilliant, evaluated the characteristics and safety of brigatinib as first-line (1L) treatment for Chinese patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Eighty-two patients were enrolled by June 2024, with a median age of 55.5 years and a median follow-up of 3.96 months. Most patients (92.7%) were at stage C, and 92.7% had two or more metastatic sites; adenocarcinoma was the predominant histology (81.7%). ALK rearrangement was confirmed via various methods including NGS (35.4%), IHC (31.7%), and PCR (25.6%).<br /><br />Brigatinib, a next-generation ALK tyrosine kinase inhibitor with CNS penetration, has shown superior efficacy and tolerability compared to crizotinib in previous phase 3 ALTA-1L trials. This study's real-world data aligned with ALTA-1L results, demonstrating good tolerability with 51.2% reporting any treatment-emergent adverse events (TRAEs). Grade 3 TRAEs occurred in 7.3% of patients. Frequent TRAEs >5% included increased aspartate aminotransferase (19.5%), creatine phosphokinase (17.1%), alanine aminotransferase (11%), and rash (6.1%). Dose modifications and interruptions due to TRAEs were low (4.9% and 3.7%, respectively), indicating better tolerability in practice.<br /><br />The study notes brigatinib’s endorsement as a preferred 1L treatment in guidelines and points out the lack of real-world data in Chinese populations until now. The ongoing study (2022–2029) will further assess real-world effectiveness, progression-free survival, response rates, resistance mechanisms, subsequent treatments, and quality of life. Results so far suggest brigatinib’s safety and applicability in routine clinical practice for Chinese ALK-positive NSCLC patients.<br /><br />This research underscores brigatinib’s role as an effective, well-tolerated first-line ALK inhibitor and supports its continued use and monitoring in diverse, real-world patient populations. The study is funded by Takeda and presented at WCLC 2025.

Asset Subtitle

Lei Wang

Meta Tag

Speaker Lei Wang

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Brigatinib

ALK-positive non-small cell lung cancer

First-line treatment

Chinese patients

Real-world study

Safety and tolerability

Treatment-emergent adverse events

ALK rearrangement detection

Advanced/metastatic NSCLC

Takeda funded study